MedTrace Logo

Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer

NCT04616131 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-11-04

No results posted yet for this study

Summary

For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Conditions

  • Pancreas Cancer

Sponsors & Collaborators

  • Elsa U. Pardee Foundation

    collaborator OTHER

  • Central DuPage Hospital

    lead OTHER

Principal Investigators

  • Akhil Chawla, MD · Northwestern Medicine Central DuPage Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-10-01
Completion
2021-10-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616131 on ClinicalTrials.gov